Topline results from a phase 1 study of AbbVie’s (ABBV) amylin analogue ABBV-295 for obesity showed the candidate led to significant weight loss at weekly, bi-weekly, and monthly dosing schedules.
At week 12 with weekly dosing, average weight loss ranged from 7.75% to -9.79%. At week 13 with every other week dosing followed by monthly dosing after week five, average weight loss ranged from -7.86% to -9.73%.
Doses examined ranged from 2 mg-14 mg.
AbbVie noted that ABBV-295 was well tolerated at all dosage strengths with no serious adverse events reported. The most common side effects reported were gastrointestinal in nature and mild.
ABBV-295 an agonist that activates amylin and calcitonin receptors, a different mechanism of action from GLP-1s that are currently dominating the obesity therapy market.
